All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAR-NK (Chimeric Antigen Receptor-Natural Killer) therapy has emerged as a promising approach for the treatment of cancer and other diseases. At Creative Biolabs, we are at the forefront of this revolution, offering the innovative ROCK™ Antibody Platform to enhance CAR-NK therapy. This groundbreaking technology leverages the power of natural killer cells in targeting cancer cells, complementing the established CAR-T cell therapy.
The primary goal of ROCK is to stimulate the body's inherent immune system or natural killer (NK) cells in order to eliminate cancerous cells. What sets our ROCK platform apart is its ability to sidestep the treatment-related side effects typically associated with T cell-based therapies, leading to better patient tolerance. The ROCK platform accomplishes this by utilizing a high-affinity anti-CD16A (also known as Fcγ RIIIa) component, which targets a distinct epitope separate from Fc binding, thereby reducing the risk of competitive binding with circulating plasma Fc. This anti-CD16 component is responsible for enlisting the help of NK cells or macrophages, similar to the role played by the anti-CD3 component in T cell-based bispecific antibodies, but with the focus on activating the innate immune response rather than the adaptive immune response. In summary, ROCK represents a highly specialized and well-suited bispecific platform for engineering NK cell engagers, designed to address some of the limitations associated with current T cell redirection approaches.
Fig.1 ROCK™ Mode of Action.
Creative Biolabs' ROCK™ Antibody Platform boasts several distinctive features that set it apart in the field of CAR-NK therapy:
Creative Biolabs is committed to advancing CAR-NK therapy with the ROCK™ Antibody Platform. Our comprehensive services encompass every aspect of the development and application of this cutting-edge technology.
Please get in touch with our expert team for more information.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION